Peter Lurie Quotations

Lead wicks are unnecessary in candles, and the industry has acted recklessly by continuing to manufacture them, ... Now the agency should complete the notice and comment necessary to complete the rule making as rapidly as possible.

Here you have an agency repeatedly asking for data of this kind, and nothing is forthcoming.

This represents clearly significant additional risks to workers.

Bribing physicians has long been held to be illegal. This advertisement essentially pays teenagers to convince adults to procure this drug for them, with the size of the payment in proportion to the amount of drug prescribed.

Enforcement levels have dropped so low that boosting them has become very easy.

This agency had to be sued in order to issue anything. Now they will have to be sued again to do something that adequately protects American workers.

For every additional conflict you have a 10 percent increased probability that the meeting will favor the company more.

It seemed to us like a disaster waiting to happen. The unique benefits of the drug were outweighed by the need to constantly monitor for liver toxicity.

Before, you couldn't get back and forth to these countries the way you can now. You couldn't share data electronically the way you can now. Even if people had the temptation to go overseas before because of less regulation, more compliant populations or study designs that they couldn't pull off locally, logistically it was not possible until recently. That's where globalization comes in.

I don't think that's good enough. People don't poke around in the latest issue looking for conflict-of-interest statements.

The underlying problems is that the FDA has little ability to enforce these commitments, short of withdrawing approval for the drug - an outcome that may not serve the public health well. The great majority of post-marketing studies address safety issues, at least in part, so patients and physicians are denied critical safety information when these studies are not completed in a timely fashion.

The underlying problem is that the FDA has little ability to enforce these commitments, short of withdrawing approval for the drug - an outcome that may not serve the public health well. The great majority of post-marketing studies address safety issues, at least in part, so patients and physicians are denied critical safety information when these studies are not completed in a timely fashion.

The circumstances regarding this study raise troubling questions about the ability of the government to effectively issue rules protecting public health when studies are conducted, controlled and selectively published.